

## Predicting outcomes of cross-sex hormone therapy in gender dysphoria based on pre-therapy resting-state brain connectivity

Teena D Moody<sup>1\*</sup>, Jamie D Feusner<sup>1\*</sup>, Nicco Reggente<sup>2,3</sup>, Jonathan Vanhoecke<sup>6</sup>, Mats Holmberg<sup>4,5</sup>, Amirhossein Manzouri<sup>4</sup>, Behzad Sorouri Khorashad<sup>4</sup>, Ivanka Savic<sup>4</sup>

<sup>1</sup> Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. <sup>2</sup> Tiny Blue Dot Foundation, Santa Monica, CA USA, <sup>3</sup> Institute for Advanced Consciousness Studies, Santa Monica, CA, USA <sup>4</sup> Karolinska Institutet, Stockholm, Sweden <sup>5</sup> ANOVA, Karolinska University Hospital, Stockholm, Sweden, <sup>6</sup> University of Southern California, Los Angeles, CA, USA

Corresponding author: [tmood@ucla.edu](mailto:tmood@ucla.edu), Teena D Moody

\* Equal first authors

**Keywords:** transgender, cross-sex hormone therapy, machine learning, LASSO.

**Author Contributions:** TDM, NR, IS, and JDF designed research; TDM, NR, AM, MH, IS, and JSF performed research; TDM, NR, IS, JV, and JDF contributed new analytic tools; TDM analyzed data; and TDM, NR, MH, AM, IS, and JDF wrote the paper.

Major subject areas: Neuroscience and Human Biology and Medicine.

### Abstract

Individuals with gender dysphoria experience life-threatening distress due to incongruence between their gender identity and birth-assigned sex. Hormone therapy can be effective for reducing body incongruence, but responses vary, and there is no reliable way to predict therapeutic outcomes. We use clinical and MRI data before cross-sex hormone therapy as features to train a machine learning model to predict individuals' post-therapy body congruence (the degree to which photos of their bodies match their self-identities). Twenty-five transwomen and transmen with gender dysphoria participated. The model significantly predicted post-therapy body congruence. This study provides evidence that hormone therapy efficacy can be predicted from information collected *before therapy* and that patterns of connectivity within fronto-parietal and cingulo-opercular networks may provide insights into body-brain effects of hormones, affecting one's sense of body congruence. Results could help identify the need for personalized therapies in individuals predicted to have low body-self congruence after standard therapy.

## Impact Statement

Outcomes of cross-sex hormone therapy in gender dysphoria can be predicted on an individual level *prior* to initiating therapy. Multivariate neuroimaging features provided superior prediction performance over clinical data alone.

## Introduction

Awareness of gender dysphoria (GD) has climbed sharply in recent years. Issues related to self-identity, body image, and medical interventions in GD are challenges for the 21st century, particularly given the high suicide risk (Clements-Nolle et al., 2006; Maguen and Shipherd, 2010; Mueller et al., 2017; Narang et al., 2018) associated with the disorder. GD, in DSM-5 (American Psychiatric Association., 2013), or gender incongruence in ICD-11 (World Health Organization, 1992), refers to significant distress and/or impairment due to a feeling of incongruence between a person's experienced gender and their birth-assigned sex. Individuals with GD comprise a subset of those who identify as transgender (*T. C. van de Grift et al., 2016*). GD has been theorized to be a consequence of incongruence between cerebral sexual differentiation (Swaab, 2004) and birth-assigned sex. Therefore, GD is usually treated with cross-sex hormone therapy (Dhejne et al., 2016; Nguyen et al., 2018), in many cases followed by gender-affirming surgery (van de Grift et al., 2018). In a large proportion of individuals, these therapies reduce the sense of incongruence and associated dysphoria, as well as ratings of depression, suicide risk, and quality of life (Dhejne et al., 2016; Murad et al., 2010; Nguyen et al., 2018; Nobili et al., 2018). In a non-trivial proportion, however, therapy is unsuccessful as evidenced by the high heterogeneity of quality of life outcomes across studies (Murad et al., 2010; Nobili et al., 2018), as well as variable improvements in body image (van de Grift et al., 2017).

The medical profession currently lacks the ability to determine who will respond well to therapy and who will not - a critical piece in moving towards personalized, evidence-based medicine to optimize clinical outcomes and efficacy of therapy. Overall there have been few studies that have examined predictors of clinical outcomes for cross-sex hormone or gender-affirming surgical treatments. A recent study of hormone and surgical treatments (van de Grift et al., 2017) found that that body dissatisfaction

pre-treatment predicted body dissatisfaction post-treatment ( $p < 0.001$ ), but there was no predictive value of birth-assigned sex ( $p = 0.83$ ), age ( $p = 0.23$ ), or physical “passing” at admission ( $p = 0.50$ ). A study of surgical treatments found better outcomes were predicted by pre-treatment lower dissatisfaction with secondary sex characteristics ( $p < 0.001$ ) and less psychopathology ( $p < 0.028$ ), as well as being homosexual ( $p < 0.002$ ) (defined in relationship to birth-assigned sex)(Smith et al., 2005).

In those with GD, the primary therapy outcomes - improving congruence between one’s gender identity and the sex-related physical characteristics of their body, as well as associated dysphoria - are conscious experiences and have a prominent basis in neural function. Consequently, not only is it of paramount importance to be able to predict therapy response, in large part this may be predicated on the underlying neurobiology.

We recently proposed a hypothesis that GD is characterized by a functional disconnection between systems in the brain that process the perception of self (“self-referential”) and those that mediate own-body perception (Majid et al., 2019),(Manzouri et al., 2017). Self-referential systems include the default mode network, particularly medial prefrontal cortical regions such as the dorsal and pregenual anterior cingulate cortex (Northoff et al., 2006), and the salience network, particularly the insular cortex (Craig and (Bud) Craig, 2010), (Uddin, 2015). Involved in own-body perception are the temporoparietal junction (Blanke et al., 2005) and the extrastriate and fusiform body areas (Vocks et al., 2010). We proposed that differences in coordinated activation and connections between own-body and self-perception networks could explain the discomfort with their bodies reported by individuals with GD (Majid et al., 2019),(Manzouri et al., 2017). To better understand relationships between body perception and gender-related self-identity, we previously designed a “body morph task” (Feusner et al., 2016), specifically to test the degree of incongruence between self own-body perception in relation to the body sex phenotype. In this task participants view their own bodies in unitards in photographs that are incrementally morphed with others’ bodies that are the same as, or opposite to, their birth-assigned sex. For each image presentation, the participant assesses to what degree the image represents him/her. We then determine the ratings of the “body morph index”: the perception of the degree of self, represented by an index calculated from ratings across *all* of the morphed bodies presented. The body morph index

provides an indication of an individual's maximal perception of 'self' on a continuum from traditionally feminine to traditionally masculine appearances.

Studies using the body morph task (Burke et al., 2018; Feusner et al., 2017, 2016; Kilpatrick et al., 2019; Majid et al., 2019) suggest that, at least in transmen, information from this task in combination with resting state fMRI may be an indication of self-perception pre-therapy, as well as the effects of hormone therapy on self-perception. Further, because the body index is calculated from multiple presentations of morphs toward and away from birth-assigned sex, it may be a more objective and precise instrument to assess body congruence compared with a subjective, self-report rating scale, e.g. the Transgender Congruence Scale (TCS), or qualitative reports. Therefore, in the current study we used the body index as our main outcome variable to quantify an individual's body congruence.

In alignment with our previous studies of structural and functional brain systems in GD, we focused on seven brain networks as potential predictive features. These networks have shown differences in brain activation (Burke et al., 2019), cortical thickness (Kilpatrick et al., 2019), or in connectivity (Feusner et al., 2017), (Uribe et al., 2020) in transgender compared with cisgender individuals. In addition to the above mentioned (i) salience and (ii) default mode networks (Manzouri and Savic, 2019), the (iii) fronto-parietal and (iv) cingulo-opercular task control networks, including dorsal and pregenual anterior cingulate cortices, are implicated in the perception of self (Northoff et al., 2006). The (v) dorsal and (vi) ventral attention networks include the temporal parietal junction and surrounding cortices important in own body perception (Blanke et al., 2005). Regions within the (vii) memory retrieval network include midline regions of the posterior cingulate shown to be important for self-perception (Manzouri et al., 2017). All network-defined regions of interest (ROIs) were derived from a brain parcellation from Power et al., (Power et al., 2011) who partitioned the brain into functional networks based on resting-state connectivity data. (See Figure S1 for node locations for a priori networks.)

For the current study, we used this knowledge of underlying biology to build a set of features capable of predicting therapeutic outcomes for GD individuals within a machine-learning framework. We focused on resting-state fMRI connectivity measures before cross-sex hormone therapy, combined with clinical data - pre-therapy body index ratings, body mass index (BMI), therapy duration, and sexual

orientation (Kinsey scores) - to train and test a penalized regression model for predicting post-hormone therapy body congruence, measured by the post-hormone therapy body index scores.

## Results

### *Participants*

Twenty-five adults ages 18-50, mean years 25.2 (SD 7.8), with DSM-diagnosed GD participated in the study. Data from 16 transwomen (assigned male at birth) and 9 transmen (assigned female at birth) were combined for all analyses. See Table 1 for demographics.

**Body Congruence Changes** For short duration trials, body index scores changed in the direction of increased congruence pre- to post hormone-therapy in 18 of 25 participants (72%), see Figure S3. The pre-therapy mean was -10.4 (SD, 21.8); the post-therapy mean was -23.1(SD, 25.7),  $t_{24} = 3.1$ ,  $p = 0.002$ , 1-tailed. Similarly, for long duration trials, change in the direction of increased congruence was observed in 15 of 25 participants (60%). The pre-therapy mean was -11.1(SD, 33.5); the post-therapy mean was -21.3 (SD, 31.7),  $t_{24} = 1.8$ ,  $p = 0.04$ , 1-tailed (Table 1). More-negative scores on the body index are indicative of greater congruence of their body with their gender identity. There were associations in a comparison of pre- and post-therapy values of body index scores: body index ratings for short duration trials ( $R^2 = 0.41$ ,  $p = 0.006$ ) and body index ratings for long duration trials ( $R^2 = 0.39$ ,  $p = 0.008$ ). There was a trend for an association between treatment duration and body index ratings after hormone therapy for short duration trials, ( $R^2 = 0.11$ ,  $p = 0.11$ ), see Figure S3.

**Table 1.** Demographics, clinical values and ratings of the participants (N=25).

Characteristic	Value	SD	P value T-test	P value correlation
Transwomen/Transmen	16/9			
Age	25.2	7.8		
BMI	24.1	5.5		
Kinsey scores	4.0	2.0		
Years of education	13.3	1.9		
Therapy duration (months)	14.3	5.4		
Body index pre-therapy short duration trials	-10.4	21.8		
Body index post-therapy short duration trials	-23.1	25.7	p=0.002*	p<0.001 <sup>+</sup>
Body index pre-therapy long duration trials	-11.1	33.5		
Body index post-therapy long duration trials	-21.3	31.7	p=0.040*	p<0.001 <sup>+</sup>

\* Paired one-tailed, t-test, comparing pre- versus post-hormone therapy.

<sup>+</sup> Correlation, comparing pre- versus post-hormone therapy.

Negative values of the body index represent ratings toward gender (congruent with sense of self in those with gender dysphoria).


## ***Body congruence prediction***

### ***Predicting post-therapy body index ratings using LASSO machine learning regression***

For these analyses, we used functional connectivity (FC) from resting-state fMRI data either a) across all nodes composing an individual network or b) across all aggregate nodes composing multiple networks. Short-duration trials (Table 2), but not long-duration trials (Table S1), predicted post-treatment body congruence. Clinical data points that were also leveraged alongside the FC values in the feature set included pre-therapy body index ratings, sexual orientation (Kinsey scores), BMI, and time from initiation of therapy. See Table S6 for similar results, without considering treatment duration.

#### *Individual a priori networks*

The associations between the algorithm's predicted post-therapy body index ratings ( $\hat{y}$ ) and the actual ratings ( $y$ ) was statistically significant when using two of the seven a priori networks, the fronto-parietal network and the cingulo-opercular network, alongside the clinical features. When only the clinical features were considered in the model, there was not an association between predicted ( $\hat{y}$ ) and actual ( $y$ ) body index values,  $R^2 = 0.24$ ,  $p = 0.013$ ; however, when the model included the clinical features and the functional connectivity, there were associations for the fronto-parietal network,  $R^2 = 0.52$ ,  $p < 0.001$  and for the cingulo-opercular network  $R^2 = 0.47$ ,  $p < 0.001$ , (Table 2, Figure 1), for Bonferroni corrected,  $p_{bf} < 0.006$ .



**Figure 1.** Associations between the distributions of body index predictions and actual post-therapy values are shown in scatter plots. These LASSO cross-validation models used feature sets that included pre-therapy functional connectivity from the cingulo-opercular network (Left) and the fronto-parietal network (Right), in addition to clinical features. Error bars are standard-errors across the 100 cross-validation predictions for each individual. The Bonferroni-corrected significance level is  $p_{bf} \leq 0.006$ .



**Table 2.** Associations between predicted post-therapy body congruence for seven brain functional connectivity networks, combined with clinical features, using multivariate analysis.

Network	R <sup>2</sup> Functional connectivity and clinical features
Fronto-parietal	0.52*
Cingulo-opercular	0.47*
Memory Retrieval	0.20
Saliency	0.19
Dorsal Attention	0.09
Ventral Attention	0.06
Default Mode	0.02
All 7 networks	0.09
<b>Exploratory post-hoc</b>	
Cingulo-opercular & Fronto-parietal	0.33*

---

\* for  $p_{bf} \leq 0.006$ , Bonferroni-corrected significance level. Clinical features alone were not significant,  $R^2 = 0.24$ .

### *Aggregated a priori networks*

Including all seven of the a priori networks in the model along with pre-therapy clinical features resulted in a lower value of  $R^2 = 0.09$ ,  $p = 0.149$ . However, combining the two networks (cingulo-opercular and fronto-parietal) that showed significant associations between predicted and actual body index ratings above, with clinical features, resulted in an association of  $R^2 = 0.32$ ,  $p = 0.003$ .

### *Predicting post-therapy body index ratings using ridge machine learning regression*

We additionally tested predictions using ridge regression. The results when including the same clinical and network features were similar to those using the LASSO models, showing associations for cingulo-opercular  $R^2 = 0.41$ ,  $p = 0.001$ , and fronto-parietal networks  $R^2 = 0.32$ ,  $p = 0.003$ , and combining the two networks  $R^2 = 0.32$ ,  $p = 0.003$ ; all significant for  $p_{\text{bf}} < 0.006$ , Table S2. Clinical features alone were not associated,  $R^2 = 0.25$ ,  $p = 0.010$ , (Table S2).

### *Post Hoc prediction of pre-therapy body index ratings*

The association between the *predicted pre-therapy* body index ratings and *actual pre-therapy* ratings for short duration trials was not significant when using clinical features and the FC of any of our a priori networks.

## **Discussion**

This study in individuals with gender dysphoria tested whether multivariate pattern recognition using neurobiological features from resting state brain connectivity along with clinical features could be used to predict therapeutic response to cross-hormone therapy. The goal was to predict, on an individual basis, the important clinical outcome of body congruence in those with gender dysphoria after hormone therapy by using brain functional connectivity data from a short (7.5 minute) MRI scan, BMI, and body congruence ratings before hormone therapy. Multivariate connectivity in the cingulo-opercular and fronto-parietal networks before hormone therapy explained a high proportion of the variance in individual body

congruence after hormone therapy. Clinical variables alone *were not able to explain* body congruence using the body index ratings. These findings have implications for identifying those who will benefit more or less from hormone therapy. Furthermore, these results support our previous finding using anatomical metrics (Kilpatrick et al., 2019; Manzouri and Savic, 2019), and contribute to identifying the specific brain networks in GD, *prior to therapy*, whose connectivity patterns are critical with respect to hormone therapy effects.

The predictive model that we built and tested was able to explain 52% of the variance in body congruence subsequent to cross-hormone therapy. The predictive power of multivariate connectivity was substantiated by the overlapping results of LASSO and ridge machine learning algorithms, which converged to provide evidence that functional connectivity from cingulo-opercular and fronto-parietal networks can be used prior to initiation of hormone therapy to predict body congruence after hormone therapy. Exploiting multivariate techniques may thus provide additional insight into the neurobiological bases of gender as well as body satisfaction. A recent study (Clemens et al., 2020) employed machine learning, based on functional connectivity, to successfully predict gender identity in four groups (trans/cis, women/men). Further, including treatment duration in our analyses generates an algorithm that has beta weights for this as a feature. Therefore, if a new person came into a clinic, entering a specific time point after therapy initiation, e.g. 6 mo, or 1 year, could provide an estimate of that person's body congruence at that time point. The algorithm that did not include treatment duration was similarly predictive (Table S6).

This work can be conceived of in the context of the evolving concept of using a functional connectome as a “fingerprint” that is an index of highly individualized latent neural organization (Finn et al., 2015). This latent neural organization is linked to response tendencies, processing of stimuli, multisensory integration, and patterns of conscious and unconscious thinking (Finn et al., 2015). The most predictive networks in the current study, the fronto-parietal and cingulo-opercular networks, comprise important regions implicated in self-identity, self-referential thinking, as well as supporting top-down control of executive functioning (Ww, 2007). While the fronto-parietal and cingulo-opercular networks are largely intraconnected and separable, they also appear to communicate, or perhaps compete, for control functions (Dosenbach et al., 2007). Koush et al (Koush et al., 2019) found that the

superior frontal gyrus (within the fronto-parietal network) modulates self-referential processes in the temporal parietal junction as well as affective valuation in ventromedial prefrontal cortex - which in turn is an important hub of the default mode network. Because in the current study the fronto-parietal and cingulo-opercular networks were predictive of post-therapy but not pre-therapy body congruence, these networks may be more specifically involved in cognitive reorganization that may occur with hormone treatment. Perhaps this could involve the directed control of conscious perception of body and body changes as they fit into one's sense of gender self-identity. If so, the pre-therapy connectivity in these networks may be markers of the degree that individuals' brain network organization is able to update one's sense of self as one's body and hormonal milieu changes. As these are cognitive control networks it might point to the directed control of self-referential thought processes with body self-awareness. This is potentially informative of the neurological underpinnings of gender identity in relation to body and hormonal status among transgender individuals as they transition.

The observation that these networks that significantly predicted *post-therapy body congruence* were not also associated with *pre-therapy body congruence* suggests that these networks may be more specifically involved in cognitive reorganization occurring with hormone treatment. One speculation, for example, is that this may identify those individuals whose multivariate connectivity pattern may index better or worse ability to bring their subjective experience of their gender identity in line with the perception of their post-hormone bodies.

Connectivity before hormone therapy within the fronto-parietal and cingulo-opercular was most predictive of body congruence for short duration trials. It is not clear why ratings of short-duration trials were more predictive of body congruence than ratings of long-duration trials. One possibility is that the longer two-second trials allow rumination that interferes with the “truer” reflexive responses required by the half-second trials. Related to this, some of the ratings for long duration trials may have been influenced by individuals' difficulty viewing the body images for longer times because of continued dysphoria triggered by viewing the images, in addition to longstanding patterns of avoidance of viewing their bodies, leading to ratings that may have been made in a cursory way and thereby not reflecting their true degree of congruence.

The body index has been used in other studies (Burke et al., 2018; Feusner et al., 2016; Kilpatrick et al., 2019; Majid et al., 2019) as a metric of body congruence. Another scale measuring body congruence is the self-report TCS. We did not have TCS scores for most of the participants in this study so did not include that metric in this analysis; however, we have examined TCS scores in two ongoing datasets and found trends for positive associations between TCS scores and the body index in individuals with GD (Supporting Information). This, in addition to significant changes in the body index pre- to post-therapy and an association between treatment duration and changes in body index ( Figure S2) lends support for the body index as a measure of treatment-sensitive body congruence.

A limitation of the current study is sample size. The cross-validation approach of leaving out 20% of the participants for model testing reduced the likelihood of overfitting. However, larger datasets would provide the opportunity to split the participants into training and testing groups for a more robust validation. In addition, validation in fully independent test sets, ideally in different settings, would determine if the results may be generalizable to other populations with GD in different geographical locations and cultural and societal environments. Due to sample size limitations we were not able to consider transmen and transwomen separately in this study. Future work should do so, since a recent report (Majid et al., 2019) has shown that transwomen generally had lower body index ratings than transmen for short duration trials and transmen rated images morphed opposite to their birth-assigned sex slightly higher than transwomen. This is in line with other work (Tim C. van de Grift et al., 2016) that found transmen had a more positive body image than transwomen. Future investigations of the mechanisms underlying the regions within the fronto-parietal and cingulo-opercular networks that drive the results seen here are warranted. In addition, while the current investigation adds to evidence that hormone therapy may enhance body congruence in gender dysphoria, changes in gonadal steroid levels have been shown to affect mood and cognition (Epperson et al., 1999), (Wierckx et al., 2013).

This study illustrates the potential for predicting hormone therapy responsiveness in individual patients with gender dysphoria. One goal of this research is to enhance therapy for the individual by providing an optimal therapy plan in terms of time and cost of therapy. Hormone therapy is expensive and requires years of commitment in most cases. A more immediate practical application of these results, if replicated, would be applying the algorithm proposed here to identify individuals for whom it may be more

critical to apply therapies *in addition to hormones* - such as gender affirming surgeries to optimize body congruence. This approach may also help identify those for whom standard hormone protocols are not expected to work as well and who may need different estrogen or androgen antagonists and/or alternate types or regimens of sex hormones, or no sex hormones. Further, results from the study could help us understand what *pre-therapy* brain networks may be involved in *post-therapy* body congruence and thus establish biomarkers that could potentially be used to develop novel ways of improving body congruence. In sum, this study contributes to understanding the neurophysiological bases of therapy in gender dysphoria. Insights from this research could contribute to future therapy guidelines for gender dysphoria.

## **Materials and Methods**

### ***Participants***

Participants were recruited in Stockholm, Sweden by the Gender Team of the Center for Andrology and Sexual Medicine at Karolinska University Hospital, a center specializing in the evaluation and therapy of individuals with gender dysphoria. Adults aged 18 to 50 who were diagnosed with Transsexualism based on ICD-10 diagnostic criteria (F64.0, World Health Organization, 1992) or gender dysphoria (GD) based on DSM-5 (American Psychiatric Association, 2013) and sought gender-affirming medical interventions were invited to enter the study. Participants were excluded for previous or current hormonal therapy, any known chromosomal or hormonal disorder, or any concurrent psychiatric disorder (determined by the Mini International Neuropsychiatric Interview, MINI, Sheehan (Sheehan and Lecrubier, 2010), neurological or other medical disorder including autism spectrum disorder, substance abuse, or the use of psychoactive medications. All participants provided full informed consent in accordance with the Karolinska Institute ethical committee (Application # Dnr 2011/281-31/4). See Supporting Information for details of hormone therapy.

### ***Data Acquisition***

Participants underwent an MRI scan and were evaluated with psychometric tools prior to hormonal therapy at session 1 (S1/pre-therapy). The participants were scanned and evaluated at session 2

(S2/post-therapy), on average 14 months later. We used S1 clinical measures and resting state functional connectivity (FC) as inputs to our machine learning algorithms to predict metrics of body satisfaction at S2, with the goal of determining which patients will benefit from hormone therapy - *prior to undergoing hormone therapy*.


### **Body Morph Task**

Details of the body morph task can be found in Burke et al. 2019 (Burke et al., 2019). Each participant was dressed in a tight, full-body unitard to provide an accurate representation of their body shape without the discomfort of being nude. Hands, feet, and head were cropped from the photos, and both front and side views were taken. Each participant's picture was morphed towards those of five different female and five different male pictures at degree intervals of 20%, using FantaMorph Software, version 5.0 (Abrosoft <http://www.fantamorph.com/>). Eleven morph conditions resulted, ranging between -100% morphed completely opposite to birth-assigned sex to +100% morphed completely towards birth-assigned sex: 0% referred to the original unmorphed own-body image. A set of 62 images (using a randomized order and number of repetitions of the body image morphs and unmorphed own-body image) were presented for two different viewing conditions (short duration=0.5s and long duration=2s), totaling 128 trials. These images were presented using Presentation® version 18.1 on a laptop computer. Each trial consisted of the image (presented for either 0.5 or 2s) followed by a 1s response screen with button press options, followed by a fixation cross. Participants were instructed to respond as quickly as possible to the question "To what degree is this picture you?" on a 4-point scale (1: 0-25% "me", 2: 25-50% "me", 3: 50-75% "me", and 4: 75-100% "me"). Before the task, participants engaged in a practice session to ensure task comprehension. The clinical data was used to extract the body index (BI) (Feusner et al., 2017) that was subsequently employed as a predictive feature in our machine learning algorithms.

### **Demographics and Psychometrics**

Clinical metrics collected at S1 were used as features or covariates of non-interest: Kinsey (Kinsey et al., 2003) sexual orientation score, body mass index (BMI), age, therapy duration (in months from initiation

of therapy) and birth-assigned sex. The predicted clinical measure was the body index score, calculated from the body morph task described below (Figure 2). The body morph task data were collected on a laptop, prior to the resting state MRI acquisition.



**Figure 2.** The body morph task asks subjects to rate morphed and unmorphed own-body images. Shown are examples of a front view male sex-assigned-at-birth photograph morphed by 20, 40, 60, 80, and 100% to a same and an opposite sex-assigned-at-birth photograph, denoted by positive and negative morph degrees, respectively. Note that 100% photographs were unaltered images of another person. The 0% image is the unaltered, unmorphed own-body photograph of the participant.



To calculate the body index, we first multiplied each degree (1-4) of “self” rated for each morph with the degree of each morph. These weighted values were averaged for each participant across ratings for all images and then divided by the number of rated images, providing an average index of self-perception for each participant, weighted by how close or far from the actual self-photograph the image was morphed, and in which direction. *Positive values of the body index represent ratings toward birth-assigned sex (incongruent), while negative values represent ratings toward gender (congruent).*

### **MR Data Acquisition**

MRI data was acquired on a 3 Tesla MRI scanner (Discovery 3T GE-MR750, General Electric, Milwaukee, Wisconsin) using a 32-channel head coil. Resting-state functional MRI data were acquired with a gradient echo pulse sequence with: voxel size of 2.25 x 2.25 x 3 mm, TR/TE=2500/30ms, FOV=28.8cm, 45 interleaved axial slices, 90° flip angle. Each resting-state scan totaled 7min 35 sec and participants were instructed to rest with eyes closed, to remain as still as possible, and not to sleep while the sequence was acquired. Structural data, 3D T1-weighted Spoiled Gradient Echo pulse sequence, were acquired with : voxel size 0.94 x 0.94 x 1 mm, TR/TE=7.91/3.06ms, TI=450ms, FOV=24 cm, 176 axial slices, 12° flip angle.

### **Data Analysis**

MRI analysis was performed using FEAT (fMRI Expert Analysis Tool) version 5.0.8, part of FSL (FMRIB Software Library <http://www.fmrib.ox.ac.uk/fsl>, (Jenkinson et al., 2012). Bold sequences were motion-corrected (FMRIB linear image registration tool MCFLIRT), without spatial smoothing, and individual participants' resting state data were denoised using FSL's AROMA tool (non-aggressive denoising option). Functional images were registered to the T1-weighted images (FMRIB non-linear image registration tool, FNIRT) after brain extraction using FSL's BET. Denoised images were then registered to their respective T1 images and to the MNI-152 brain for functional connectivity analysis. Two participants were excluded from further analyses due to head motion greater than 1.5 mm.

### ***ROI Selection***


We used a functionally-defined set of ROIs (10mm diameter spheres) that have been previously mapped to functional networks (Power et al., 2011), (Reggente et al., 2018). We narrowed our scope to seven *a priori* networks that covered regions and networks with functional and/or structural differences between cisgender and GD or transgender individuals: default mode, fronto-parietal, dorsal attention, salience, cingulo-opercular, memory retrieval, and ventral attention. This resulted in 264 ROIs, each of which was tagged with one of seven functional-network identities.

### ***ROI correlation matrices***

We collected resting-state data from each participant prior to cross-hormone therapy and used the denoised images to determine connectivity among the ROIs. For each participant we computed the mean BOLD activity within each of the ROIs at every time point (every 2.5 seconds), resulting in a time course of mean ROI activity. We then computed a pairwise Pearson correlation matrix for each mean time course resulting in 264 x 264 matrices containing the pairwise functional connectivity values (r-values) across all ROIs.

### ***Feature Creation***

We indexed each correlation matrix depending on network identity, extracting the lower diagonal of each matrix and then identifying the rows and columns corresponding to the functional connectivity across ROIs within a specific network. These constituted the functional connectivity (FC) feature sets. We included these feature sets plus clinical data, as the “hand-selected” features that we tested in the machine learning algorithms. See Figure 3 for a flow chart of the machine learning analysis. Unless otherwise indicated, all predictions were tested for significance of  $p < .05$  and were subjected to the Bonferroni method to correct for multiple comparisons, The Bonferroni-adjusted p-value,  $p_{bf} < 0.006$  ( $p < 0.05/9$ ), was adjusted by the seven networks in our *a priori* hypotheses, and two combinations of networks (all seven networks and the fronto-parietal and cingulo-opercular networks together).



**Figure 3.** Analysis flow chart. (A) The average resting-state activity within ROIs from seven functional brain networks defined by Power (30) was used to create a mean BOLD time course. Pairwise Pearson correlations of these time courses resulted in a functional connectivity matrix specific for each network. (B) The lower diagonal of each participant’s network-specific matrix was concatenated with the participant’s pre-therapy clinical features scores to create a feature set for that participant. (C) The LASSO regression model was trained on  $n-5$  participants’ feature sets and their associated post-therapy body index scores and used to predict each of the left-out participant’s post-therapy body index scores. Left-out participants are denoted as highlighted feature sets (only three shown here). This process was repeated until all participants had been left out in a fold of the cross-validation and had been assigned a predicted post-therapy body index score. We correlated the array of predicted values ( $\hat{y}$ ) with the actual values ( $y$ ), resulting in Pearson’s  $R^2$ , a measure of our model’s feature-dependent ability to capture the outcome variable variance across participants. Note that due to our participant sample size ( $n = 25$ ), one fold of the cross-validation left out five participants.

### ***Machine learning regression analysis predicting post-therapy body index using absolute shrinkage and selection operator (LASSO)***

We built a LASSO (Tibshirani, 1996)<sup>3</sup>, (Reggente et al., 2018) regression model on n=5 (20%) participants using their feature sets. LASSO was chosen as the regression model of choice due to its ability to handle large feature sets, impose a self-directed feature selection, and output continuous variables. Using each trained model's intercept term and beta coefficients, we calculated a predicted measure of interest from each left-out participant's feature set. After obtaining a prediction for each participant ( $\hat{y}$ ), we correlated the array of predicted values with the actual values ( $y$ ) to quantify the model's feature-dependent ability to capture the variance in clinical measures across participants.

Clinical features included pre-therapy body index rating, therapy duration, BMI, and Kinsey scores. Age was treated as a covariate of non-interest and iteratively regressed out of each feature in the feature set prior to classification. We did not include birth-assigned sex as a covariate, as it is considered within the body index ratings. For predicting body index for short duration trials, we used the pre-therapy body index ratings for short duration trials as a feature, likewise, for predicting pre-therapy body index for long duration trials, we used the body index ratings for long duration trials as a feature. In a preliminary analysis, we examined the effect of therapy duration in our analyses by including therapy duration either as a covariate or as a clinical feature. For six of the seven networks, using therapy duration as a feature was more predictive than using therapy duration as a covariate (Table S3); therefore, results reported for body index are for therapy duration as a feature (Table 2).

### ***Machine learning prediction of post-therapy body index using ridge regression***

To provide a robustness check on our LASSO predictions, we re-ran the above machine learning analysis using ridge (Marquardt and Snee, 1975) regression. Ridge regression is appropriate when the predictor features potentially have collinearity. (See Table S5, also see Table S4 for additional post-hoc tests of robustness.)

## Acknowledgments

This work was supported by the Swedish Science Council (Dnr 200 7-3107 to I.S) and the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (1R01HD087712 to I.S. and J.F.) We thank Natalie Rotstein for assistance with data validation.

## References

- American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders: DSM-5, 5th ed. Washington, DC: American Psychiatric Association.
- American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub.
- Blanke O, Mohr C, Michel CM, Pascual-Leone A, Brugger P, Seeck M, Landis T, Thut G. 2005. Linking out-of-body experience and self processing to mental own-body imagery at the temporoparietal junction. *J Neurosci* **25**:550–557.
- Burke SM, Majid DSA, Manzouri AH, Moody T, Feusner JD, Savic I. 2019. Sex differences in own and other body perception. *Hum Brain Mapp* **40**:474–488.
- Burke SM, Manzouri AH, Dhejne C, Bergström K, Arver S, Feusner JD, Savic-Berglund I. 2018. Testosterone Effects on the Brain in Transgender Men. *Cereb Cortex* **28**:1582–1596.
- Clemens B, Derntl B, Smith E, Junger J, Neulen J, Mingoia G, Schneider F, Abel T, Bzdok D, Habel U. 2020. Predictive Pattern Classification Can Distinguish Gender Identity Subtypes from Behavior and Brain Imaging. *Cereb Cortex* **30**:2755–2765.
- Clements-Nolle K, Marx R, Katz M. 2006. Attempted suicide among transgender persons: The influence of gender-based discrimination and victimization. *J Homosex* **51**:53–69.
- Craig AD (bud), (Bud) Craig AD. 2010. The sentient self. *Brain Struct Funct* **214**:563–577.
- Dhejne C, Van Vlerken R, Heylens G, Arcelus J. 2016. Mental health and gender dysphoria: A review of the literature. *Int Rev Psychiatry* **28**:44–57.

- Dosenbach NUF, Fair DA, Miezin FM, Cohen AL, Wenger KK, Dosenbach RAT, Fox MD, Snyder AZ, Vincent JL, Raichle ME, Schlaggar BL, Petersen SE. 2007. Distinct brain networks for adaptive and stable task control in humans. *Proc Natl Acad Sci U S A* **104**:11073–11078.
- Epperson CN, Wisner KL, Yamamoto B. 1999. Gonadal steroids in the treatment of mood disorders. *Psychosom Med* **61**:676–697.
- Feusner JD, Dervisic J, Kosidou K, Dhejne C, Bookheimer S, Savic I. 2016. Female-to-Male Transsexual Individuals Demonstrate Different Own Body Identification. *Arch Sex Behav* **45**:525–536.
- Feusner JD, Lidström A, Moody TD, Dhejne C, Bookheimer SY, Savic I. 2017. Intrinsic network connectivity and own body perception in gender dysphoria. *Brain Imaging Behav* **11**:964–976.
- Finn ES, Shen X, Scheinost D, Rosenberg MD, Huang J, Chun MM, Papademetris X, Constable RT. 2015. Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. *Nat Neurosci* **18**:1664–1671.
- Grift TC van de, van de Grift TC, Cohen-Kettenis PT, Elaut E, De Cuyper G, Richter-Appelt H, Haraldsen IR, Kreukels BPC. 2016. A network analysis of body satisfaction of people with gender dysphoria. *Body Image*. doi:10.1016/j.bodyim.2016.04.002
- Grift TC van de, van de Grift TC, Cohen-Kettenis PT, Steensma TD, De Cuyper G, Richter-Appelt H, Haraldsen IRH, Dikmans REG, Cerwenka SC, Kreukels BPC. 2016. Body Satisfaction and Physical Appearance in Gender Dysphoria. *Archives of Sexual Behavior*. doi:10.1007/s10508-015-0614-1
- Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. 2012. Fsl. *Neuroimage* **62**:782–790.
- Kilpatrick LA, Holmberg M, Manzouri A, Savic I. 2019. Cross sex hormone treatment is linked with a reversal of cerebral patterns associated with gender dysphoria to the baseline of cisgender controls. *Eur J Neurosci* **50**:3269–3281.
- Kinsey AC, Pomeroy WR, Martin CE. 2003. Sexual Behavior in the Human Male. *Am J Public Health* **93**:894–898.
- Koush Y, Pichon S, Eickhoff SB, Van De Ville D, Vuilleumier P, Scharnowski F. 2019. Brain networks for engaging oneself in positive-social emotion regulation. *NeuroImage*. doi:10.1016/j.neuroimage.2018.12.049
- Maguen S, Shipherd JC. 2010. Suicide risk among transgender individuals. *Psychology & Sexuality* **1**:34–

43.

Majid DSA, Burke SM, Manzouri A, Moody TD, Dhejne C, Feusner JD, Savic I. 2019. Neural Systems for Own-body Processing Align with Gender Identity Rather Than Birth-assigned Sex. *Cereb Cortex*.

doi:10.1093/cercor/bhz282

Manzouri A, Kosidou K, Savic I. 2017. Anatomical and Functional Findings in Female-to-Male Transsexuals: Testing a New Hypothesis. *Cereb Cortex* **27**:998–1010.

Manzouri A, Savic I. 2019. Possible Neurobiological Underpinnings of Homosexuality and Gender Dysphoria. *Cereb Cortex* **29**:2084–2101.

Marquardt DW, Snee RD. 1975. Ridge Regression in Practice. *Am Stat* **29**:3–20.

Mueller SC, De Cuypere G, T'Sjoen G. 2017. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. *Am J Psychiatry* **174**:1155–1162.

Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ, Montori VM. 2010. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. *Clinical Endocrinology*. doi:10.1111/j.1365-2265.2009.03625.x

Narang P, Sarai SK, Aldrin S, Lippmann S. 2018. Suicide Among Transgender and Gender-Nonconforming People. *Prim Care Companion CNS Disord* **20**. doi:10.4088/PCC.18nr02273

Nguyen HB, Chavez AM, Lipner E, Hantsoo L, Kornfield SL, Davies RD, Neill Epperson C. 2018. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition. *Current Psychiatry Reports*. doi:10.1007/s11920-018-0973-0

Nobili A, Glazebrook C, Arcelus J. 2018. Quality of life of treatment-seeking transgender adults: A systematic review and meta-analysis. *Rev Endocr Metab Disord* **19**:199–220.

Northoff G, Heinzl A, de Greck M, BERPohl F, Dobrowolny H, Panksepp J. 2006. Self-referential processing in our brain--a meta-analysis of imaging studies on the self. *Neuroimage* **31**:440–457.

Power JD, Cohen AL, Nelson SM, Wig GS, Barnes KA, Church JA, Vogel AC, Laumann TO, Miezin FM, Schlaggar BL, Petersen SE. 2011. Functional network organization of the human brain. *Neuron* **72**:665–678.

Reggente N, Moody TD, Morfini F, Sheen C, Rissman J, O'Neill J, Feusner JD. 2018. Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive–

- compulsive disorder. *Proc Natl Acad Sci U S A* **115**:2222–2227.
- Sheehan D, Lecrubier Y. 2010. Mini international neuropsychiatric interview version 6.0 (MINI 6.0)--The international standard (MINI 6.0).
- Smith YLS, Van Goozen SHM, Kuiper AJ, Cohen-Kettenis PT. 2005. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. *Psychol Med* **35**:89–99.
- Swaab DF. 2004. Sexual differentiation of the human brain: relevance for gender identity, transsexualism and sexual orientation. *Gynecological Endocrinology*. doi:10.1080/09513590400018231
- Tibshirani R. 1996. Regression Shrinkage and Selection Via the Lasso. *J R Stat Soc Series B Stat Methodol* **58**:267–288.
- Uddin LQ. 2015. Salience processing and insular cortical function and dysfunction. *Nat Rev Neurosci* **16**:55–61.
- Uribe C, Junque C, Gómez-Gil E, Abos A, Mueller SC, Guillamon A. 2020. Brain network interactions in transgender individuals with gender incongruence. *Neuroimage* **211**:116613.
- van de Grift TC, Elaut E, Cerwenka SC, Cohen-Kettenis PT, De Cuypere G, Richter-Appelt H, Kreukels BPC. 2017. Effects of Medical Interventions on Gender Dysphoria and Body Image: A Follow-Up Study. *Psychosom Med* **79**:815–823.
- van de Grift TC, Elaut E, Cerwenka SC, Cohen-Kettenis PT, Kreukels BPC. 2018. Surgical Satisfaction, Quality of Life, and Their Association After Gender-Affirming Surgery: A Follow-up Study. *J Sex Marital Ther* **44**:138–148.
- Vocks S, Busch M, Grönemeyer D, Schulte D, Herpertz S, Suchan B. 2010. Differential neuronal responses to the self and others in the extrastriate body area and the fusiform body area. *Cogn Affect Behav Neurosci* **10**:422–429.
- Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, Kaufman JM, T'Sjoen G. 2013. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control study. *European Journal of Endocrinology*. doi:10.1530/eje-13-0493
- World Health Organization. 1992. The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. World Health Organization.
- Ww S. 2007. Menon V. Schatzberg AF. Keller J. Glover GH. Kenna H. Reiss AL. Greicius MD.



Dissociable intrinsic connectivity networks for salience processing and executive control. *J Neurosci*  
**27**:2349–2356.